2018 Critical Limb Ischemia (CLI) Drug Development- Pipeline Analysis Report
Critical Limb Ischemia (CLI) is a catastrophic condition representing the most advanced phase of peripheral arterial disease. Patients witness strong blocking of the arteries, resulting in decreased blood flow thereby, resulting in acute pain, loss of tissues and claudication. The condition is a result of arteriosclerosis, which leads to extreme low arterial blood flow in lower limbs.
Lack of therapeutic options cause amputation being the current options and typical survival rates of amputations is below 30%. Diabetes, smoking and hypertension are the major risk aspects of the condition.
An estimated 1.8 million patients suffer from Critical Limb Ischemia worldwide, with an estimated market size of $10 to $12 billion.
Critical Limb Ischemia pipeline comprises of 27 active drugs under active development as of April 2018. Of these, 2 drugs are in Phase 1 and 16 drugs in phase 2, 2 drugs in Phase 3. Further, 6 drugs are in Pre-clinical stage and 1 drug in pre-registration stage.
43 companies are developing the pipeline for Critical Limb Ischemia. Of this, Rexgenero Ltd. has highest number of compounds in pipeline. Mechanism of Action of most of the therapeutic candidates is Cell replacements.
One compound has been awarded FDA fast track status for Critical Limb Ischemia.
To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Critical Limb Ischemia (CLI) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Critical Limb Ischemia (CLI) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Critical Limb Ischemia (CLI) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Lack of therapeutic options cause amputation being the current options and typical survival rates of amputations is below 30%. Diabetes, smoking and hypertension are the major risk aspects of the condition.
An estimated 1.8 million patients suffer from Critical Limb Ischemia worldwide, with an estimated market size of $10 to $12 billion.
Critical Limb Ischemia pipeline comprises of 27 active drugs under active development as of April 2018. Of these, 2 drugs are in Phase 1 and 16 drugs in phase 2, 2 drugs in Phase 3. Further, 6 drugs are in Pre-clinical stage and 1 drug in pre-registration stage.
43 companies are developing the pipeline for Critical Limb Ischemia. Of this, Rexgenero Ltd. has highest number of compounds in pipeline. Mechanism of Action of most of the therapeutic candidates is Cell replacements.
One compound has been awarded FDA fast track status for Critical Limb Ischemia.
To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Critical Limb Ischemia (CLI) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Critical Limb Ischemia (CLI) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Critical Limb Ischemia (CLI) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 CRITICAL LIMB ISCHEMIA- COMPANY WISE PIPELINE ANALYSIS
3.1 Anaeropharma Science, Inc. PIPELINE, H1 2018
3.2 AnGes MG, Inc. PIPELINE, H1 2018
3.3 Apceth Biopharma GmbH PIPELINE, H1 2018
3.4 Athersys, Inc. PIPELINE, H1 2018
3.5 BioGenCell Ltd. PIPELINE, H1 2018
3.6 Biotech Holdings PIPELINE, H1 2018
3.7 Caladrius Biosciences, Inc PIPELINE, H1 2018
3.8 Constant Pharmaceuticals LLC PIPELINE, H1 2018
3.9 Cynata Therapeutics Limited PIPELINE, H1 2018
3.10 Hemostemix Inc PIPELINE, H1 2018
3.11 Histocell, S.L PIPELINE, H1 2018
3.12 ID Pharma Co., Ltd PIPELINE, H1 2018
3.13 Juventas Therapeutics, Inc. PIPELINE, H1 2018
3.14 Kasiak Research Pvt. Ltd PIPELINE, H1 2018
3.15 LifeCells LLC PIPELINE, H1 2018
3.16 Pharmicell Co., Ltd. PIPELINE, H1 2018
3.17 Pluristem Therapeutics Inc PIPELINE, H1 2018
3.18 ReNeuron Group plc PIPELINE, H1 2018
3.19 Reven Pharmaceuticals Inc PIPELINE, H1 2018
3.20 Rexgenero Ltd PIPELINE, H1 2018
3.21 Symic Bio, Inc PIPELINE, H1 2018
3.22 TikoMed AB PIPELINE, H1 2018
3.23 U.S. Stem Cell Inc PIPELINE, H1 2018
3.24 VESSL Therapeutics Ltd. PIPELINE, H1 2018
3.25 ViroMed Co Ltd PIPELINE, H1 2018
4 CRITICAL LIMB ISCHEMIA DRUG SNAPSHOTS
4.1 FGF2 producing B. longum Drug Details
4.1.1 Snapshot
4.1.2 Drug Overview
4.1.3 Mechanism of Action
4.1.4 Current Status
4.1.5 Trial Details
4.2 AMG0001 Drug Details
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.2.5 Trial Details
4.3 Alecmestencel-T Drug Details
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.3.5 Trial Details
4.4 PF-05285401 Drug Details
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.4.5 Trial Details
4.5 BGC101 Drug Details
4.5.1 Snapshot
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.5.5 Trial Details
4.6 ProCell Microbiome Activated Stem Cell Therapy Details
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.6.5 Trial Details
4.7 CLBS-12 Drug Details
4.7.1 Snapshot
4.7.2 Drug Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.7.5 Trial Details
4.8 TXA302 Drug Details
4.8.1 Snapshot
4.8.2 Drug Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.8.5 Trial Details
4.9 Cymerus MSCs Drug Details
4.9.1 Snapshot
4.9.2 Drug Overview
4.9.3 Mechanism of Action
4.9.4 Current Status
4.9.5 Trial Details
4.10 ACP-01 Drug Details
4.10.1 Snapshot
4.10.2 Drug Overview
4.10.3 Mechanism of Action
4.10.4 Current Status
4.10.5 Trial Details
4.11 HC016 Drug Details
4.11.1 Snapshot
4.11.2 Drug Overview
4.11.3 Mechanism of Action
4.11.4 Current Status
4.12 DVC1-0101 Drug Details
4.12.1 Snapshot
4.12.2 Drug Overview
4.12.3 Mechanism of Action
4.12.4 Current Status
4.12.5 Trial Details
4.13 JVS-100 Drug Details
4.13.1 Snapshot
4.13.2 Drug Overview
4.13.3 Mechanism of Action
4.13.4 Current Status
4.13.5 Trial Details
4.14 Autologous Adipose Derieved MSCs Drug Details
4.14.1 Snapshot
4.14.2 Drug Overview
4.14.3 Mechanism of Action
4.14.4 Current Status
4.14.5 Trial Details
4.15 ASCT01 Drug Details
4.15.1 Snapshot
4.15.2 Drug Overview
4.15.3 Mechanism of Action
4.15.4 Current Status
4.15.5 Trial Details
4.16 PLX-PAD Drug Details
4.16.1 Snapshot
4.16.2 Drug Overview
4.16.3 Mechanism of Action
4.16.4 Current Status
4.16.5 Trial Details
4.17 CTX stem cell therapy Details
4.17.1 Snapshot
4.17.2 Drug Overview
4.17.3 Mechanism of Action
4.17.4 Current Status
4.17.5 Trial Details
4.18 Rejuveinix Drug Details
4.18.1 Snapshot
4.18.2 Drug Overview
4.18.3 Mechanism of Action
4.18.4 Current Status
4.18.5 Trial Details
4.19 REX-001 Drug Details
4.19.1 Snapshot
4.19.2 Drug Overview
4.19.3 Mechanism of Action
4.19.4 Current Status
4.19.5 Trial Details
4.20 REX-002 Drug Details
4.20.1 Snapshot
4.20.2 Drug Overview
4.20.3 Mechanism of Action
4.20.4 Current Status
4.20.5 Trial Details
4.21 REX-003 Drug Details
4.21.1 Snapshot
4.21.2 Drug Overview
4.21.3 Mechanism of Action
4.21.4 Current Status
4.21.5 Trial Details
4.22 SB-030 Drug Details
4.22.1 Snapshot
4.22.2 Drug Overview
4.22.3 Mechanism of Action
4.22.4 Current Status
4.22.5 Trial Details
4.23 TM-700 Drug Details
4.23.1 Snapshot
4.23.2 Drug Overview
4.23.3 Mechanism of Action
4.23.4 Current Status
4.24 Adipose derived stem cell Details
4.24.1 Snapshot
4.24.2 Drug Overview
4.24.3 Mechanism of Action
4.24.4 Current Status
4.25 MultiGeneAngio (MGA) Drug Details
4.25.1 Snapshot
4.25.2 Drug Overview
4.25.3 Mechanism of Action
4.25.4 Current Status
4.25.5 Trial Details
4.26 VM202-PAD Drug Details
4.26.1 Snapshot
4.26.2 Drug Overview
4.26.3 Mechanism of Action
4.26.4 Current Status
4.26.5 Trial Details
4.27 Cellgram-CLI Drug Details
4.27.1 Snapshot
4.27.2 Drug Overview
4.27.3 Mechanism of Action
4.27.4 Current Status
4.27.5 Trial Details
5 RECENT DEVELOPMENTS IN CRITICAL LIMB ISCHEMIA PIPELINE
5.1 Caladrius Biosciences Awarded Expedited Review Designation in Japan - 2018
5.2 Intact Vascular plans $22 million - 2018
5.3 AnGes MG Files NDA in Japan for CLI - 2018
5.4 Biorasi and Biotech Holdings collaborate to development treatment options for Critical Limb Ischemia - 2017
5.5 BioTech Holdings Announces clinical safety data for Microbiome Optimized Autologous Stem Cells- 2017
5.6 Histocell and VITALVIA collaborate to promote the commercialisation in Spain of the new product for wound healing Reoxcare- 2017
5.7 ReNeuron completes recruitment of Phase I trial in critical limb ischaemia
5.8 Rexgenero treats first patient in its Phase III programme with lead product REX-001, a novel cell therapy for the treatment of Critical Limb Ischemia (CLI)- 2018
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 CRITICAL LIMB ISCHEMIA- COMPANY WISE PIPELINE ANALYSIS
3.1 Anaeropharma Science, Inc. PIPELINE, H1 2018
3.2 AnGes MG, Inc. PIPELINE, H1 2018
3.3 Apceth Biopharma GmbH PIPELINE, H1 2018
3.4 Athersys, Inc. PIPELINE, H1 2018
3.5 BioGenCell Ltd. PIPELINE, H1 2018
3.6 Biotech Holdings PIPELINE, H1 2018
3.7 Caladrius Biosciences, Inc PIPELINE, H1 2018
3.8 Constant Pharmaceuticals LLC PIPELINE, H1 2018
3.9 Cynata Therapeutics Limited PIPELINE, H1 2018
3.10 Hemostemix Inc PIPELINE, H1 2018
3.11 Histocell, S.L PIPELINE, H1 2018
3.12 ID Pharma Co., Ltd PIPELINE, H1 2018
3.13 Juventas Therapeutics, Inc. PIPELINE, H1 2018
3.14 Kasiak Research Pvt. Ltd PIPELINE, H1 2018
3.15 LifeCells LLC PIPELINE, H1 2018
3.16 Pharmicell Co., Ltd. PIPELINE, H1 2018
3.17 Pluristem Therapeutics Inc PIPELINE, H1 2018
3.18 ReNeuron Group plc PIPELINE, H1 2018
3.19 Reven Pharmaceuticals Inc PIPELINE, H1 2018
3.20 Rexgenero Ltd PIPELINE, H1 2018
3.21 Symic Bio, Inc PIPELINE, H1 2018
3.22 TikoMed AB PIPELINE, H1 2018
3.23 U.S. Stem Cell Inc PIPELINE, H1 2018
3.24 VESSL Therapeutics Ltd. PIPELINE, H1 2018
3.25 ViroMed Co Ltd PIPELINE, H1 2018
4 CRITICAL LIMB ISCHEMIA DRUG SNAPSHOTS
4.1 FGF2 producing B. longum Drug Details
4.1.1 Snapshot
4.1.2 Drug Overview
4.1.3 Mechanism of Action
4.1.4 Current Status
4.1.5 Trial Details
4.2 AMG0001 Drug Details
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.2.5 Trial Details
4.3 Alecmestencel-T Drug Details
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.3.5 Trial Details
4.4 PF-05285401 Drug Details
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.4.5 Trial Details
4.5 BGC101 Drug Details
4.5.1 Snapshot
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.5.5 Trial Details
4.6 ProCell Microbiome Activated Stem Cell Therapy Details
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.6.5 Trial Details
4.7 CLBS-12 Drug Details
4.7.1 Snapshot
4.7.2 Drug Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.7.5 Trial Details
4.8 TXA302 Drug Details
4.8.1 Snapshot
4.8.2 Drug Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.8.5 Trial Details
4.9 Cymerus MSCs Drug Details
4.9.1 Snapshot
4.9.2 Drug Overview
4.9.3 Mechanism of Action
4.9.4 Current Status
4.9.5 Trial Details
4.10 ACP-01 Drug Details
4.10.1 Snapshot
4.10.2 Drug Overview
4.10.3 Mechanism of Action
4.10.4 Current Status
4.10.5 Trial Details
4.11 HC016 Drug Details
4.11.1 Snapshot
4.11.2 Drug Overview
4.11.3 Mechanism of Action
4.11.4 Current Status
4.12 DVC1-0101 Drug Details
4.12.1 Snapshot
4.12.2 Drug Overview
4.12.3 Mechanism of Action
4.12.4 Current Status
4.12.5 Trial Details
4.13 JVS-100 Drug Details
4.13.1 Snapshot
4.13.2 Drug Overview
4.13.3 Mechanism of Action
4.13.4 Current Status
4.13.5 Trial Details
4.14 Autologous Adipose Derieved MSCs Drug Details
4.14.1 Snapshot
4.14.2 Drug Overview
4.14.3 Mechanism of Action
4.14.4 Current Status
4.14.5 Trial Details
4.15 ASCT01 Drug Details
4.15.1 Snapshot
4.15.2 Drug Overview
4.15.3 Mechanism of Action
4.15.4 Current Status
4.15.5 Trial Details
4.16 PLX-PAD Drug Details
4.16.1 Snapshot
4.16.2 Drug Overview
4.16.3 Mechanism of Action
4.16.4 Current Status
4.16.5 Trial Details
4.17 CTX stem cell therapy Details
4.17.1 Snapshot
4.17.2 Drug Overview
4.17.3 Mechanism of Action
4.17.4 Current Status
4.17.5 Trial Details
4.18 Rejuveinix Drug Details
4.18.1 Snapshot
4.18.2 Drug Overview
4.18.3 Mechanism of Action
4.18.4 Current Status
4.18.5 Trial Details
4.19 REX-001 Drug Details
4.19.1 Snapshot
4.19.2 Drug Overview
4.19.3 Mechanism of Action
4.19.4 Current Status
4.19.5 Trial Details
4.20 REX-002 Drug Details
4.20.1 Snapshot
4.20.2 Drug Overview
4.20.3 Mechanism of Action
4.20.4 Current Status
4.20.5 Trial Details
4.21 REX-003 Drug Details
4.21.1 Snapshot
4.21.2 Drug Overview
4.21.3 Mechanism of Action
4.21.4 Current Status
4.21.5 Trial Details
4.22 SB-030 Drug Details
4.22.1 Snapshot
4.22.2 Drug Overview
4.22.3 Mechanism of Action
4.22.4 Current Status
4.22.5 Trial Details
4.23 TM-700 Drug Details
4.23.1 Snapshot
4.23.2 Drug Overview
4.23.3 Mechanism of Action
4.23.4 Current Status
4.24 Adipose derived stem cell Details
4.24.1 Snapshot
4.24.2 Drug Overview
4.24.3 Mechanism of Action
4.24.4 Current Status
4.25 MultiGeneAngio (MGA) Drug Details
4.25.1 Snapshot
4.25.2 Drug Overview
4.25.3 Mechanism of Action
4.25.4 Current Status
4.25.5 Trial Details
4.26 VM202-PAD Drug Details
4.26.1 Snapshot
4.26.2 Drug Overview
4.26.3 Mechanism of Action
4.26.4 Current Status
4.26.5 Trial Details
4.27 Cellgram-CLI Drug Details
4.27.1 Snapshot
4.27.2 Drug Overview
4.27.3 Mechanism of Action
4.27.4 Current Status
4.27.5 Trial Details
5 RECENT DEVELOPMENTS IN CRITICAL LIMB ISCHEMIA PIPELINE
5.1 Caladrius Biosciences Awarded Expedited Review Designation in Japan - 2018
5.2 Intact Vascular plans $22 million - 2018
5.3 AnGes MG Files NDA in Japan for CLI - 2018
5.4 Biorasi and Biotech Holdings collaborate to development treatment options for Critical Limb Ischemia - 2017
5.5 BioTech Holdings Announces clinical safety data for Microbiome Optimized Autologous Stem Cells- 2017
5.6 Histocell and VITALVIA collaborate to promote the commercialisation in Spain of the new product for wound healing Reoxcare- 2017
5.7 ReNeuron completes recruitment of Phase I trial in critical limb ischaemia
5.8 Rexgenero treats first patient in its Phase III programme with lead product REX-001, a novel cell therapy for the treatment of Critical Limb Ischemia (CLI)- 2018
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
LIST OF FIGURES
Figure 1: Critical Limb Ischemia Pipeline by Phase, H1- 2018
Figure 2: Critical Limb Ischemia Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Critical Limb Ischemia Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
Figure 1: Critical Limb Ischemia Pipeline by Phase, H1- 2018
Figure 2: Critical Limb Ischemia Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Critical Limb Ischemia Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Critical Limb Ischemia Pipeline by Phase, H1- 2018
Table 2: Critical Limb Ischemia Pipeline by Companies, H1- 2018 (1)
Table 3: Critical Limb Ischemia Pipeline by Companies, H1- 2018 (2)
Table 4: Critical Limb Ischemia Pipeline by Mechanism of Action, H1- 2018
Table 5: Anaeropharma Science, Inc. Critical Limb Ischemia Pipeline, H1- 2018
Table 6: AnGes MG, Inc. - Critical Limb Ischemia Pipeline, H1- 2018
Table 7: Apceth Biopharma GmbH Critical Limb Ischemia Pipeline, H1- 2018
Table 8: Athersys, Inc. - Critical Limb Ischemia Pipeline, H1- 2018
Table 9: BioGenCell Ltd. Critical Limb Ischemia Pipeline, H1- 2018
Table 10: Biotech Holdings - Critical Limb Ischemia Pipeline, H1- 2018
Table 11: Caladrius Biosciences, Inc Critical Limb Ischemia Pipeline, H1- 2018
Table 12: Constant Pharmaceuticals LLC - Critical Limb Ischemia Pipeline, H1- 2018
Table 13: Cynata Therapeutics Limited Critical Limb Ischemia Pipeline, H1- 2018
Table 14: Hemostemix Inc - Critical Limb Ischemia Pipeline, H1- 2018
Table 15: Histocell, S.L Critical Limb Ischemia Pipeline, H1- 2018
Table 16: ID Pharma Co., Ltd- Critical Limb Ischemia Pipeline, H1- 2018
Table 17: Juventas Therapeutics, Inc. Critical Limb Ischemia Pipeline, H1- 2018
Table 18: Kasiak Research Pvt. Ltd - Critical Limb Ischemia Pipeline, H1- 2018
Table 19: LifeCells LLC Critical Limb Ischemia Pipeline, H1- 2018
Table 20: Pharmicell Co., Ltd. Critical Limb Ischemia Pipeline, H1- 2018
Table 21: Pluristem Therapeutics Inc- Critical Limb Ischemia Pipeline, H1- 2018
Table 22: ReNeuron Group plc Critical Limb Ischemia Pipeline, H1- 2018
Table 23: Reven Pharmaceuticals Inc- Critical Limb Ischemia Pipeline, H1- 2018
Table 24: Rexgenero Ltd Critical Limb Ischemia Pipeline, H1- 2018
Table 25: Symic Bio, Inc - Critical Limb Ischemia Pipeline, H1- 2018
Table 26: TikoMed AB Critical Limb Ischemia Pipeline, H1- 2018
Table 27: U.S. Stem Cell Inc - Critical Limb Ischemia Pipeline, H1- 2018
Table 28: VESSL Therapeutics Ltd. Critical Limb Ischemia Pipeline, H1- 2018
Table 29: - Critical Limb Ischemia Pipeline, H1- 2018
Table 1: Critical Limb Ischemia Pipeline by Phase, H1- 2018
Table 2: Critical Limb Ischemia Pipeline by Companies, H1- 2018 (1)
Table 3: Critical Limb Ischemia Pipeline by Companies, H1- 2018 (2)
Table 4: Critical Limb Ischemia Pipeline by Mechanism of Action, H1- 2018
Table 5: Anaeropharma Science, Inc. Critical Limb Ischemia Pipeline, H1- 2018
Table 6: AnGes MG, Inc. - Critical Limb Ischemia Pipeline, H1- 2018
Table 7: Apceth Biopharma GmbH Critical Limb Ischemia Pipeline, H1- 2018
Table 8: Athersys, Inc. - Critical Limb Ischemia Pipeline, H1- 2018
Table 9: BioGenCell Ltd. Critical Limb Ischemia Pipeline, H1- 2018
Table 10: Biotech Holdings - Critical Limb Ischemia Pipeline, H1- 2018
Table 11: Caladrius Biosciences, Inc Critical Limb Ischemia Pipeline, H1- 2018
Table 12: Constant Pharmaceuticals LLC - Critical Limb Ischemia Pipeline, H1- 2018
Table 13: Cynata Therapeutics Limited Critical Limb Ischemia Pipeline, H1- 2018
Table 14: Hemostemix Inc - Critical Limb Ischemia Pipeline, H1- 2018
Table 15: Histocell, S.L Critical Limb Ischemia Pipeline, H1- 2018
Table 16: ID Pharma Co., Ltd- Critical Limb Ischemia Pipeline, H1- 2018
Table 17: Juventas Therapeutics, Inc. Critical Limb Ischemia Pipeline, H1- 2018
Table 18: Kasiak Research Pvt. Ltd - Critical Limb Ischemia Pipeline, H1- 2018
Table 19: LifeCells LLC Critical Limb Ischemia Pipeline, H1- 2018
Table 20: Pharmicell Co., Ltd. Critical Limb Ischemia Pipeline, H1- 2018
Table 21: Pluristem Therapeutics Inc- Critical Limb Ischemia Pipeline, H1- 2018
Table 22: ReNeuron Group plc Critical Limb Ischemia Pipeline, H1- 2018
Table 23: Reven Pharmaceuticals Inc- Critical Limb Ischemia Pipeline, H1- 2018
Table 24: Rexgenero Ltd Critical Limb Ischemia Pipeline, H1- 2018
Table 25: Symic Bio, Inc - Critical Limb Ischemia Pipeline, H1- 2018
Table 26: TikoMed AB Critical Limb Ischemia Pipeline, H1- 2018
Table 27: U.S. Stem Cell Inc - Critical Limb Ischemia Pipeline, H1- 2018
Table 28: VESSL Therapeutics Ltd. Critical Limb Ischemia Pipeline, H1- 2018
Table 29: - Critical Limb Ischemia Pipeline, H1- 2018
